Manara - Qatar Research Repository
10.1186_s13046-022-02318-0.pdf (1.5 MB)

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer

Download (1.5 MB)
journal contribution
submitted on 2024-04-21, 08:07 and posted on 2024-04-21, 08:08 authored by Afsheen Raza, Abdul Q. Khan, Varghese Philipose Inchakalody, Sarra Mestiri, Zeenath Safira K. M. Yoosuf, Takwa Bedhiafi, Dina Moustafa Abo El-Ella, Nassiba Taib, Shereena Hydrose, Shayista Akbar, Queenie Fernandes, Lobna Al-Zaidan, Roopesh Krishnankutty, Maysaloun Merhi, Shahab Uddin, Said Dermime

Colorectal cancer (CRC) is one of the most common cancers worldwide. The diagnosis, prognosis and therapeutic monitoring of CRC depends largely on tissue biopsy. However, due to tumor heterogeneity and limitations such as invasiveness, high cost and limited applicability in longitudinal monitoring, liquid biopsy has gathered immense attention in CRC. Liquid biopsy has several advantages over tissue biopsy including ease of sampling, effective monitoring, and longitudinal assessment of treatment dynamics. Furthermore, the importance of liquid biopsy is signified by approval of several liquid biopsy assays by regulatory bodies indicating the powerful approach of liquid biopsy for comprehensive CRC screening, diagnostic and prognostics. Several liquid biopsy biomarkers such as novel components of the microbiome, non-coding RNAs, extracellular vesicles and circulating tumor DNA are extensively being researched for their role in CRC management. Majority of these components have shown promising results on their clinical application in CRC including early detection, observe tumor heterogeneity for treatment and response, prediction of metastases and relapse and detection of minimal residual disease. Therefore, in this review, we aim to provide updated information on various novel liquid biopsy markers such as a) oral microbiota related bacterial network b) gut microbiome-associated serum metabolites c) PIWI-interacting RNAs (piRNAs), microRNA(miRNAs), Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and d) circulating tumor DNAs (ctDNA) and circulating tumor cells (CTC) for their role in disease diagnosis, prognosis, treatment monitoring and their applicability for personalized management of CRC.

Other Information

Published in: Journal of Experimental & Clinical Cancer Research
See article on publisher's website:



  • English


Springer Nature

Publication Year

  • 2022

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • National Center for Cancer Care and Research - HMC
  • Interim Translational Research Institute - HMC
  • Dermatology Institute - HMC
  • Hamad Bin Khalifa University
  • College of Health and Life Sciences - HBKU

Usage metrics

    College of Health and Life Sciences - HBKU



    Ref. manager